Volume Alert - ISIS 50.72 Isis Pharmaceuticals $ISIS Hit a

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - ISIS 50.72 Isis Pharmaceuticals $ISIS Hit a high today of 50.75 Closing the day 10:30 at 50.72 -0.67 -1.30% With a day low of 49.46 and a total volume of 1,808,241.

ISIS Recent Posts: http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/

ISIS Isis Pharmaceuticals Recent Headline News

Critical Alerts For Twitter, Isis Pharmaceuticals, TrueCar and Myriad Genetics Released By InvestorsObserver
PR Newswire - Wed Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, ISIS, TRUE and MYGN.
MYGN: 33.01 (+0.68), ISIS: 51.25 (-0.14), TRUE: 17.33 (-0.16), TWTR: 40.94 (+1.35)

Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
PR Newswire - Wed Nov 12, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes" in a private placement. Isis also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $75.0 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The sale of the Convertible Notes is expected to close on November 17, 2014, subject to customary closing conditions.
ISIS: 51.25 (-0.14)

Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.42 (-0.07), DHI: 24.16 (+0.21), AMZN: 311.16 (-0.85), TSLA: 249.63 (-1.45), KR: 58.14 (-0.14), SWY: 34.89 (-0.01), CLX: 101.61 (+0.26), XOM: 95.99 (-0.42), FCAU: 11.67 (+0.25), INO: 11.08 (-0.22), WHR: 174.61 (-0.39), T: 35.39 (+0.29), ISIS: 51.25 (-0.14), VALE: 8.86 (-0.06), EOG: 98.37 (-0.38), HAWK: 37.20 (+0.37), SHW: 236.45 (-1.17), VZ: 50.98 (+0.37), TOL: 33.78 (+0.06), REGN: 399.88 (+1.52), KELYA: 15.44 (+0.26), BABA: 118.46 (+3.92)

Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.16 (+0.21), TSLA: 249.63 (-1.45), AMZN: 311.16 (-0.85), CY: 10.13 (-0.02), XOM: 95.99 (-0.42), KEX: 106.17 (+0.13), LRN: 12.92 (-0.01), BWLD: 161.73 (-0.84), ADBE: 71.58 (-0.12), GTLS: 45.99 (+0.19), TWX: 77.63 (-0.41), WHR: 174.61 (-0.39), T: 35.39 (+0.29), LYB: 87.28 (-1.26), ISIS: 51.25 (-0.14), CMG: 663.79 (+7.14), EOG: 98.37 (-0.38), HAWK: 37.20 (+0.37), SHW: 236.45 (-1.17), VZ: 50.98 (+0.37), DOW: 49.76 (+0.24), REGN: 399.88 (+1.52), KELYA: 15.44 (+0.26), CBS: 51.43 (-0.41)

Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 8.81%
Comtex SmarTrend(R) - Tue Nov 11, 3:42PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.10 to a high of $52.24. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $47.25 on volume of 10.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 51.25 (-0.14)

One Reason Isis Pharmaceuticals (ISIS) Stock Is Gaining Today
at The Street - Tue Nov 11, 10:24AM CST
Isis Pharmaceuticals (ISIS) stock is up after the company announced it will offer $425 million in convertible senior notes.
ISIS: 51.25 (-0.14)

Isis Pharmaceuticals to launch USD425m convertible senior notes in private placement
M2 - Tue Nov 11, 6:57AM CST
Antisense drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Monday that it plans to offer USD425.0m aggregate principal amount of convertible senior notes due 2021 in a private placement.
ISIS: 51.25 (-0.14)

Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
PR Newswire - Mon Nov 10, 3:03PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes" in a private placement. Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $63.75 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any.
ISIS: 51.25 (-0.14)

ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:52PM CST

ISIS: 51.25 (-0.14)

34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 51.25 (-0.14)

Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 51.25 (-0.14)

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 321.57 (-3.02), ALNY: 99.24 (+0.77), ISIS: 51.25 (-0.14), OGXI: 2.11 (-0.04), TEVA: 58.46 (+0.27), RGLS: 19.99 (-0.48), GSK: 45.60 (-0.36), SNY: 46.29 (-0.85)

Isis ups revenues 87% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:53AM CST

ISIS: 51.25 (-0.14)

Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 51.25 (-0.14)

Isis Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:33AM CST

ISIS: 51.25 (-0.14)

Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 51.25 (-0.14)

Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 321.57 (-3.02), ISIS: 51.25 (-0.14)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.56 (-0.02), ERF: 15.47 (+0.25), LXP: 11.03 (+0.09), PGEM: 12.98 (-0.07), CCOI: 34.62 (+0.16), TTI: 8.65 (-0.05), SJI: 57.89 (-0.31), NXST: 45.55 (+0.70), VSAT: 63.58 (+0.69), MT: 11.97 (-0.21), LXU: 32.10 (+0.88), HUM: 136.70 (+0.26), PGNX: 6.48 (+0.20), MHR: 4.93 (+0.22), CTB: 32.69 (+0.02), IDRA: 2.48 (-0.10), ISIS: 51.25 (-0.14), BPL: 79.01 (+0.43), SSP: 18.90 (+0.50), AGIO: 86.71 (+4.80), EBIX: 16.53 (-0.14)

All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.25 (-0.14), SNY: 46.29 (-0.85)

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 321.57 (-3.02), ISIS: 51.25 (-0.14)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 161

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 127

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 118

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 89

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 222

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 154

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Insights: S&P 500 Forecasted Decline and Job Growth Impact

Updated Category News Views 107

Market Insights on Economic Factors Impacting S&P 500 Recent reports have revealed that the job market in the United States is displaying significant strength. According to recent statistics, there was an addition of 256,000 jobs, which paints a picture of a robust economy. However, this strong job growth can bring mixed signals for investors regarding the stock market,...

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 65

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Celebrating 50 Years of Excellence at Amerijet Airlines

Updated Category News Views 200

Amerijet International Airlines: A Milestone Celebration Amerijet International Airlines proudly celebrates its 50th anniversary this year, marking five decades of dedication to air cargo services that connect diverse regions. Founded by David Bassett in 1974, the airline began its journey as a small Part 135 air-taxi operator, operating a single leased aircraft. Over the...

Continue Reading
Petit Pot Wins $100K Prize at 2024 Real California Milk Event

Updated Category News Views 195

Petit Pot Celebrates a Momentous Achievement in Dairy Innovation In an exciting showcase of dairy innovation, Petit Pot has emerged as the grand prize winner of the 2024 Real California Milk (RCM) Excelerator competition. This prestigious award highlights the company's commitment to producing high-quality dairy-based desserts and its remarkable sales achievements in a...

Continue Reading
Exploring the Affordability and Safety Debate in Autos

Updated Category News Views 295

Affordability Angst, and a Scapegoat Nobody Asked For Echoes of old policy fights come roaring back here—every time car prices spike, somebody points at safety rules like they’re the boogeyman under the bed (and, yeah, it kinda ticks me off). Lawmakers have been poking at features like Auto Emergency Braking, and the broader affordability debate has gotten tangled up...

Continue Reading